In the context of ALL, Gal-3 was found significantly increased, at the protein level, in the BM plasma of ALL patients compared to HDs [122] and, at the mRNA level, in BM mononuclear cells isolated from r/r ALL patients compared to patients responding to therapy [122]. This evidence concerns the gene LGALS3 and acute lymphoblastic leukemia.